Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosibelimab + Chemotherapy in First-Line Non-Squamous NSCLC
NCT04786964Phase 3Terminated
- Sponsor
- Checkpoint Therapeutics, Inc.
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Therapeutic Vaccines
- Countries
- 8
01
Overview
A Phase 3 trial of cosibelimab-ipdl in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Checkpoint Therapeutics, Inc.. Started Dec 2021; status: terminated.
02
Drugs
cosibelimab-ipdl
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04786964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786964.